At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study of Cancer Related Fatigue in Patients With Metastatic Cancer Receiving Anti-PD1 Immunotherapy
In Brief
A Phase 3 clinical trial evaluating Laboratory Biomarker Analysis, Methylphenidate, and 4 other interventions for Advanced Malignant Neoplasm and 2 related conditions. Active but no longer recruiting, targeting 212 participants across 1 site.
Detailed Summary
This phase III trial studies how well methylphenidate and physical activity works in reducing cancer-related fatigue in patients who are receiving anti-PD1 immunotherapy for cancer that has spread to other places in the body. Central nervous systems stimulants, such as methylphenidate, may help to improve cognitive function. Physical activity uses techniques, such as aerobic and resistance exercises, which may help to improve quality of life. Giving methylphenidate and physical activity may help in reducing cancer-related fatigue in patients with metastatic cancer who receive anti-PD1 immunotherapy.
Study Details
Timeline
Interventions
Correlative studies
Given PO
Participate in physical activity
Given PO
Ancillary studies
Ancillary studies